U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H20N2O2S
Molecular Weight 328.429
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LIRANAFTATE

SMILES

COC1=CC=CC(=N1)N(C)C(=S)OC2=CC3=C(CCCC3)C=C2

InChI

InChIKey=VPHPQNGOVQYUMG-UHFFFAOYSA-N
InChI=1S/C18H20N2O2S/c1-20(16-8-5-9-17(19-16)21-2)18(23)22-15-11-10-13-6-3-4-7-14(13)12-15/h5,8-12H,3-4,6-7H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C18H20N2O2S
Molecular Weight 328.429
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Liranafate (6-methoxy-2-N-methyl-aminopyridine-thiocarboxylic acid-(5,6,7,8 tetrahydro)-β-Naphthyl ester), a new antifungal drug, is synthesis inhibitor of squalene epoxidase inhibitor and cytoderm inhibitor, which was manufactured by Tosoh Corporation and Zenyaku Kogyo Corporation. It firstly came to the market in August 2000 in Japan. By inhibiting the squalene epoxide reactions of fungal cells and detering the synthesis of ergosterol, which is a constituent of cell membrane. The antifungal activity of Liranafate is 8 times as high as that of Tolnaftate. Liranafate is especially effective against trichophyton rubrum.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Unknown
Curative
Unknown
Curative
Unknown
Curative
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
2% cream applied once a day.
Route of Administration: Topical
In Vitro Use Guide
production of IL-8 was profoundly suppressed by the addition of liranaftate to the culture in a dose-dependent manner.
Substance Class Chemical
Record UNII
5253IGO5X3
Record Status Validated (UNII)
Record Version